These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 34388040)

  • 1. Medicolegal Considerations in the Management of Opioid Use Disorder With Buprenorphine in the Correctional Setting.
    Mitchell M
    J Correct Health Care; 2021 Sep; 27(3):210-214. PubMed ID: 34388040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons.
    Treitler PC; Enich M; Reeves D; Crystal S
    Subst Abus; 2022; 43(1):964-971. PubMed ID: 35420973
    [No Abstract]   [Full Text] [Related]  

  • 3. Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.
    Sufrin C; Sutherland L; Beal L; Terplan M; Latkin C; Clarke JG
    Addiction; 2020 Nov; 115(11):2057-2065. PubMed ID: 32141128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.
    Brezel ER; Powell T; Fox AD
    Subst Abus; 2020; 41(2):150-154. PubMed ID: 31800376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Best Practices for Pregnant Incarcerated Women With Opioid Use Disorder.
    Peeler M; Fiscella K; Terplan M; Sufrin C
    J Correct Health Care; 2019 Jan; 25(1):4-14. PubMed ID: 30616487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rates of opioid agonist treatment prescribing in provincial prisons in Ontario, Canada, 2015-2018: a repeated cross-sectional analysis.
    Bodkin C; Bondy S; Regenstreif L; Kiefer L; Kouyoumdjian F
    BMJ Open; 2021 Nov; 11(11):e048944. PubMed ID: 34794988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.
    Malta M; Varatharajan T; Russell C; Pang M; Bonato S; Fischer B
    PLoS Med; 2019 Dec; 16(12):e1003002. PubMed ID: 31891578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Initial Management of Incarcerated Pregnant Women With Opioid Use Disorder.
    O'Connor A; Bowling N
    J Correct Health Care; 2020 Jan; 26(1):17-26. PubMed ID: 31960750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.
    Russell C; Nafeh F; Pang M; MacDonald SF; Derkzen D; Rehm J; Fischer B
    BMC Public Health; 2022 Mar; 22(1):436. PubMed ID: 35246083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medications for Opioid Use Disorder During Incarceration.
    McDermott-Winger ER; Latham CL
    J Addict Nurs; 2022 Jul-Sep 01; 33(3):182-190. PubMed ID: 36041161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence and treatment of opioid use disorders among primary care patients in six health systems.
    Lapham G; Boudreau DM; Johnson EA; Bobb JF; Matthews AG; McCormack J; Liu D; Samet JH; Saxon AJ; Campbell CI; Glass JE; Rossom RC; Murphy MT; Binswanger IA; Yarborough BJH; Bradley KA;
    Drug Alcohol Depend; 2020 Feb; 207():107732. PubMed ID: 31835068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State.
    Banta-Green CJ; Owens MD; Williams JR; Sears JM; Floyd AS; Williams-Gilbert W; Kingston S
    Addict Sci Clin Pract; 2022 Jul; 17(1):34. PubMed ID: 35799210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medications for management of opioid use disorder.
    Koehl JL; Zimmerman DE; Bridgeman PJ
    Am J Health Syst Pharm; 2019 Jul; 76(15):1097-1103. PubMed ID: 31361869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Injecting Opioid Use Disorder Treatment in Jails and Prisons: The Potential of Extended-release Buprenorphine in the Carceral Setting.
    Berk J; Del Pozo B; Rich JD; Lee JD
    J Addict Med; 2022 Jul-Aug 01; 16(4):396-398. PubMed ID: 34954747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geographic analysis of military health system (MHS) buprenorphine prescribers and patients.
    Issa F; Nguyen C; Abili OD; Quah RF; Engler MI; Greenberg JG; Giunta MR; Gobourne CPA; Osik AJ; Hodgson CJA; Spevak C
    J Opioid Manag; 2021; 17(7):87-100. PubMed ID: 34520030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Evolving Medicolegal Precedent for Medications for Opioid Use Disorder in U.S. Jails and Prisons.
    Toyoshima T; McNiel DE; Schonfeld A; Binder R
    J Am Acad Psychiatry Law; 2021 Dec; 49(4):545-552. PubMed ID: 34341145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of buprenorphine prescribing for the advanced practice psychiatric nurse.
    Kameg B; Fradkin D; Lepore M
    Perspect Psychiatr Care; 2022 Oct; 58(4):2059-2063. PubMed ID: 35092616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioid Use Disorder in Pregnancy.
    Roper V; Cox KJ
    J Midwifery Womens Health; 2017 May; 62(3):329-340. PubMed ID: 28561914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the availability of medications for opioid use disorder in prisons and jails in the United States during the COVID-19 pandemic.
    Dadiomov D; Trotzky-Sirr R; Shooshtari A; Qato DM
    Drug Alcohol Depend; 2022 Mar; 232():109291. PubMed ID: 35033953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.